Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N4-methyl-N4-(3-methyl-1H-indazol-6-yl)-N2-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
N4-methyl-N4-(3-methyl-1H-indazol-6-yl)-N2-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine is a synthetic small molecule compound with the molecular formula C22H24N6O3 and a molecular weight of approximately 420.47 Da[1][2][5]. It is classified as an experimental drug and does not have an assigned CAS number or UNII[2]. The compound features a pyrimidinediamine core substituted with methyl and indazole groups as well as a trimethoxyphenyl moiety. There is no publicly available information on its mechanism of action or therapeutic indication in humans; it appears to be primarily used in research settings[1][2][5].
- Other names
- N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamineN~4~-Methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)-2,4-pyrimidindiamin
02
Targets
CDK9 (Cyclin-dependent kinase 9)VEGFR2 (Vascular endothelial growth factor receptor 2)CDK2 (Cyclin-dependent kinase 2)
Beyond the preview
Go deeper on N4-methyl-N4-(3-methyl-1H-indazol-6-yl)-N2-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N4-methyl-N4-(3-methyl-1H-indazol-6-yl)-N2-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine.